Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Anixa Biosciences (CY71) AI Stock Analysis

3 Followers
DE:CY71

Anixa Biosciences

(Frankfurt:CY71)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Intellectual Property ExpansionThe expansion of Anixa's patent portfolio in China strengthens its competitive position and potential for future commercialization in a major market.
Negative Factors
Negative Cash FlowsPersistent negative cash flows challenge liquidity and sustainability, potentially limiting the company's ability to fund ongoing operations and growth.

Anixa Biosciences (CY71) vs. iShares MSCI Germany ETF (EWG)

-50%-40%-30%-20%-10%0%10%20%30%DE:CY71-23.04%EWG+6.47%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 105.33M
Dividend Yield
―
Average Volume (3M)
934
Price to Earnings (P/E)
-9.9
Beta (1Y)
0.62
Revenue Growth
―
EPS Growth
15.83%
Country
Germany
Employees
4
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Anixa Biosciences Business Overview & Revenue Model

Company Description

Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious di...

Anixa Biosciences Risk Analysis

Anixa Biosciences disclosed 40 risk factors in its most recent earnings report. Anixa Biosciences reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Anixa Biosciences Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:CY71 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ADCTADCT51Neutral$219.59M-2.4844.63%―3.03%57.71%
QSIQSI50Neutral$282.36M-2.97-47.12%―-52.96%30.51%
SEERSEER41Neutral$94.13M-1.34-27.23%―-13.23%12.29%
CUECUE34Underperform$144.13M-0.67-1032.19%―354.37%-63.33%
NKTXNKTX27Underperform$123.91M-0.91-39.64%――-6.70%

* Healthcare Sector Average

Performance Comparison

-50%0%50%DE:CY71CUEADCTNKTXSEERQSIDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:CY71 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:CY71Anixa Biosciences2.75-0.85-23.47%
CUECue Biopharma18.01-2.42-11.83%
ADCTADC Therapeutics Ltd1.64-2.57-61.05%
NKTXNkarta, Inc.1.57-0.39-19.90%
SEERSeer, Inc.1.63-0.46-22.01%
QSIQuantum-Si Incorporated1.17-0.43-26.88%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.